Izrael - angličtina - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ziprasidone mesylate trihydrate - powder for solution for injection - ziprasidone mesylate trihydrate 40.93 mg - ziprasidone - ziprasidone - rapid control of agitation in patients with schizophrenia, when oral therapy is not appropriate, for a maximum of 3 consecutive days.

Spojené státy - angličtina - NLM (National Library of Medicine)

a-s medication solutions - ziprasidone mesylate (unii: 3x6sax83jz) (ziprasidone - unii:6uka5vej6x) - geodon is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. geodon intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)] . prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)]

Namibie - angličtina - Namibia Medicines Regulatory Council

aventis pharma (pty) limited - dolasetron mesilate - tablets - dolasetron mesilate tablets 200 mg

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - dolasetron mesilate 100mg;  ;   - film coated tablet - 100 mg - active: dolasetron mesilate 100mg     excipient: carnauba wax croscarmellose sodium lactose monohydrate opacode opadry pink ys-1-14518-a pregelatinised maize starch white beeswax

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - dolasetron mesilate 200mg;  ;   - film coated tablet - 200 mg - active: dolasetron mesilate 200mg     excipient: carnauba wax croscarmellose sodium lactose monohydrate opacode opadry pink pregelatinised maize starch white beeswax

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - dolasetron mesilate 25mg;  ;   - film coated tablet - 25 mg - active: dolasetron mesilate 25mg     excipient: carnauba wax croscarmellose sodium lactose monohydrate opacode opadry white ys-1-18027-a pregelatinised maize starch white beeswax

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - dolasetron mesilate 50mg;  ;   - film coated tablet - 50 mg - active: dolasetron mesilate 50mg     excipient: carnauba wax croscarmellose sodium lactose monohydrate opacode opadry pink ys-1-14555-a pregelatinised maize starch white beeswax

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - dolasetron mesilate 20 mg/ml;   - solution for injection - 20 mg/ml - active: dolasetron mesilate 20 mg/ml   excipient: mannitol sodium acetate trihydrate water for injection

Spojené státy - angličtina - NLM (National Library of Medicine)

roerig - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 20 mg - geodon is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. geodon intramuscular is indicated for acute agitation in schizophrenic patients. when deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the qt/qtc interval compared to several other antipsychotic drugs [see warnings and precautions (5.3)] . prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see warnings and precautions (5.3)]

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited - dolasetron mesylate - tablets - 50 milligram